Amylyx Pharmaceuticals (AMLX) Finished Goods (2022)
Amylyx Pharmaceuticals (AMLX) posted quarterly Finished Goods of $937000.0 for Q4 2022, up 751.82% quarter-over-quarter from $110000.0 in Q3 2022.
Amylyx Pharmaceuticals (AMLX) Finished Goods (2022) Analysis & Trends
Amylyx Pharmaceuticals' Finished Goods history runs 1 years deep, the most recent figure standing at $937000.0 for Q4 2022.
- In Q4 2022, Finished Goods changed N/A year-over-year to $937000.0; the TTM figure through Dec 2022 stood at $937000.0 (changed N/A YoY), while the FY2022 annual figure was $937000.0, changed N/A from the prior year.
- Finished Goods for Q4 2022 stood at $937000.0, up from $110000.0 in the prior quarter.
- The five-year high for Finished Goods was $937000.0 in Q4 2022, with the low at $110000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 937,000.00 |
| Sep 30, 2022 | 110,000.00 |